The efficacy of osteoporotic treatment in patients with new spinal vertebral compression fracture pain, ADL, QOL, bone metabolism and fracture-healing - In comparison with weekly teriparatide with bisphosphonate.

Shigenobu K, Hashimoto T, Kanayama M, Ohha H, Yamane S

Bone reports25 Jul 2019Cited by 27 (Europe PMC)

PMID31440529PMCIDPMC6700423DOI10.1016/j.bonr.2019.100217PepBankPUB-31440529

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with vertebral compression fractures, weekly teriparatide improved RDQ disability more than bisphosphonate, significantly at 24 weeks.
In plain wordsIn patients with vertebral fractures, weekly teriparatide improved disability more than bisphosphonate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseRDQ disability
Study
n = 43
Comparator
Bisphosphonate
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The W-TPTD group showed a better Roland-Morris disability Questionnaire (RDQ) improvement throughout the whole period of the study compared with the BP group, the difference was statistically significant after 24 weeks of administration (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized control study to compare the effects of pain, QOL, bone metabolism and fracture healing by administering bisphosphonate (BP) or weekly teriparatide preparation (W-TPTD) to 43 patients (5 males and 38 females) with fresh spinal vertebral compression fractures for osteoporosis.
Report a problemFND-3144052902
02HumanRandomized controlled trialEfficacy outcome
In patients with vertebral compression fractures, weekly teriparatide increased fracture-healing rates compared with bisphosphonate.
In plain wordsIn patients with vertebral fractures, weekly teriparatide improved fracture healing more than bisphosphonate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFracture healing at Week 12
Study
n = 43
Comparator
Bisphosphonate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Fracture healing
73%
teriparatide
Fracture healing
45%
bisphosphonate
Source sentences
Summary
The fracture-healing rate was observed in 45% of the BP group and 73% of the W-TPTD group at Week 12, and a statistically significant higher fracture-healing rate was obtained in the W-TPTD group compared to the BP group (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized control study to compare the effects of pain, QOL, bone metabolism and fracture healing by administering bisphosphonate (BP) or weekly teriparatide preparation (W-TPTD) to 43 patients (5 males and 38 females) with fresh spinal vertebral compression fractures for osteoporosis.
Report a problemFND-3144052905
03HumanRandomized controlled trialEfficacy outcome
In patients with vertebral compression fractures, weekly teriparatide shortened fracture-healing time compared with bisphosphonate.
In plain wordsIn patients with vertebral fractures, healing was faster with weekly teriparatide than bisphosphonate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTime to fracture healing
Study
n = 43
Comparator
Bisphosphonate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Healing time
2.8 months
teriparatide
Healing time
3.9 months
bisphosphonate
Source sentences
Summary
The mean time of fracture-healing was 3.9 months for the BP group and 2.8 months in the W-TPTD group.
2 context sentences(design, population, supporting numbers)
Summary · context
Statistically significant faster fracture-healing was observed in the W-TPTD group (p < 0.05).
Summary · context
We conducted a randomized control study to compare the effects of pain, QOL, bone metabolism and fracture healing by administering bisphosphonate (BP) or weekly teriparatide preparation (W-TPTD) to 43 patients (5 males and 38 females) with fresh spinal vertebral compression fractures for osteoporosis.
Report a problemFND-3144052906
04HumanRandomized controlled trialMechanism
In patients with vertebral compression fractures, P1NP was higher with weekly teriparatide than bisphosphonate at Week 12 and Week 24.
In plain wordsIn patients with vertebral fractures, a bone formation marker was higher with teriparatide than bisphosphonate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseP1NP
Study
n = 43
Comparator
Bisphosphonate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
At Week 12 and Week 24, P1NP was significantly higher in the W-TPTD group compared to that of the BP group (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized control study to compare the effects of pain, QOL, bone metabolism and fracture healing by administering bisphosphonate (BP) or weekly teriparatide preparation (W-TPTD) to 43 patients (5 males and 38 females) with fresh spinal vertebral compression fractures for osteoporosis.
Report a problemFND-3144052907

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In patients with vertebral compression fractures, lumbar spine BMD increased in both weekly teriparatide and bisphosphonate groups.
In plain wordsIn patients with vertebral fractures, spine bone density increased in both teriparatide and bisphosphonate groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD
Study
n = 43
Comparator
Bisphosphonate
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD change
4.9%
weekly teriparatide
BMD change
5.3%
bisphosphonate
Source sentences
Summary
From this study, lumbar spine bone mineral density (BMD), after 24 weeks of administration, showed a significant increase (p < 0.05) in both the BP group (mean 5.3%) and in the W-TPTD group (mean 4.9%).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized control study to compare the effects of pain, QOL, bone metabolism and fracture healing by administering bisphosphonate (BP) or weekly teriparatide preparation (W-TPTD) to 43 patients (5 males and 38 females) with fresh spinal vertebral compression fractures for osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3144052901
06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In patients with vertebral compression fractures, EQ-5D scores improved over time in both teriparatide and bisphosphonate groups.
In plain wordsIn patients with vertebral fractures, quality of life improved in both teriparatide and bisphosphonate groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEQ-5D quality of life
Study
n = 43
Comparator
Bisphosphonate
Outcome group
Quality of life · Whole body
Source sentences
Summary
The EuroQol 5 dimensions (EQ-5D) and visual analogue scale (VAS) score significantly improved over time in both groups (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized control study to compare the effects of pain, QOL, bone metabolism and fracture healing by administering bisphosphonate (BP) or weekly teriparatide preparation (W-TPTD) to 43 patients (5 males and 38 females) with fresh spinal vertebral compression fractures for osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3144052903
07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In patients with vertebral compression fractures, VAS scores improved over time in both teriparatide and bisphosphonate groups.
In plain wordsIn patients with vertebral fractures, pain scores improved in both teriparatide and bisphosphonate groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseVAS pain score
Study
n = 43
Comparator
Bisphosphonate
Outcome group
Pain · Musculoskeletal
Source sentences
Summary
The EuroQol 5 dimensions (EQ-5D) and visual analogue scale (VAS) score significantly improved over time in both groups (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized control study to compare the effects of pain, QOL, bone metabolism and fracture healing by administering bisphosphonate (BP) or weekly teriparatide preparation (W-TPTD) to 43 patients (5 males and 38 females) with fresh spinal vertebral compression fractures for osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3144052904
08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialMechanism
In patients with vertebral compression fractures, TRACP-5b showed no major fluctuations in either teriparatide or bisphosphonate groups.
In plain wordsIn patients with vertebral fractures, a bone resorption marker showed no major changes in either treatment group.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTRACP-5b
Study
n = 43
Comparator
Bisphosphonate
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
TRACP-5b showed no major fluctuations during the study period in either group.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized control study to compare the effects of pain, QOL, bone metabolism and fracture healing by administering bisphosphonate (BP) or weekly teriparatide preparation (W-TPTD) to 43 patients (5 males and 38 females) with fresh spinal vertebral compression fractures for osteoporosis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3144052908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.